This was the stock's second consecutive day of losses.

Dec 16 - Regeneron Pharmaceuticals (REGN.O), opens new tab has settled allegations that it misused a patented protein to test its COVID-19 treatment REGEN-COV, according to filings in New York ...

Biotech giant Regeneron Pharmaceuticals REGN witnessed a massive surge in sales in 2021, driven by an exemplary contribution from REGEN-COV, a cocktail of two monoclonal antibodies — casirivimab ...

Initially, Regeneron stock continued to climb, hitting an all-time peak of $739 in April, but when the company confirmed that it did not expect to make any further sales REGEN-COV, the share began ...

Summary Regeneron has just released its Q2 2022 earnings - revenues decreased by 44% year-on-year, to $2.86bn, but increased by 20% ex-REGEN-COV revenues.

Those studies include REGEN-COV as a treatment in high-risk patients younger than 12 years old, plus a prevention study in immunocompromised teens and adults. Regeneron also put the kibosh on a ...

Regeneron Pharmaceuticals Inc. said Thursday that the Food and Drug Administration extended the review time by three months on whether to fully approve Regen-Cov as a treatment for non ...

Just as Regeneron’s COVID-19 antibody combination, REGEN-COV, is sidelined in the U.S. thanks to omicron, the drug has hit a hiccup on its quest for a full FDA nod. | Just as Regeneron’s COVID ...

In other words, even without REGEN-COV, Regeneron's business looks strong. The company will face tough year-over-year comparisons in 2022, but it's essential to look beyond that.

Full-Year Results For 2021, Regeneron generated revenues of $16.07 billion, up 89% on the back of solid performance from REGEN-COV. Excluding REGEN-COV, total revenues rose 19% in 2021.

The pharmaceutical maker has a slate of human monoclonal antibodies that target the coronavirus including REGEN-COV and other “next-generation antibodies,” the company said.